cobenfy bristol myers squibb news

Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval

Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.

Forbes · 13h

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.

MM&M · 4h

Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

The Motley Fool25d

2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High

Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...

Morningstar1d

Bristol-Myers Squibb Co

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Yahoo Finance25d

Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?

Importantly, Bristol-Myers Squibb Company (NYSE:BMY) does carry debt. But should shareholders be worried about its use of debt? Debt assists a business until the business has trouble paying it ...

1hon MSN

Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug

CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results